Progress in clinical research of subcutaneous immunoglobulin
Immunoglobulin is recognized to be used for the treatment of various diseases,not only because it can serve as an alternative therapy against infections,but also because of its immunomodulatory effects.Appropriate use of immunoglobulins can save lives.However,its route of administration may lead to many adverse events and potential other adverse consequences.At present,intravenous immunoglobulin is the main clinical use in China,but there are more adverse events in the process of clinical use,and the patient compliance is not high.Due to this unmet clinical need,subcutaneous immunoglobulin(SCIg)has been developed abroad,which has been used in multiple clinical indications.However,SCIg in China is still in the early stage of exploration and research and development.Faced with the huge clinical needs in China,domestic blood product research and development companies have been encouraged to accelerate the research and development of SCIg drugs of different specifications and different indications to meet the treatment needs of domestic patients.This article reviewed the latest clinical research progress of SCIg in the treatment of primary immunodeficiency diseases,autoimmune neuromuscular diseases and other rare diseases,in order to provide new research and development ideas and suggestions for blood product research and development enterprises in China.
NETL
NSTL
万方数据
